Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurology, inflammation, and immunology (NI&I), recently announced an inducement stock option grant. On January 26, 2026, the Company’s Board of Directors Compensation Committee awarded a non-qualified stock option to a new non-executive employee, allowing them to purchase 23,000 shares of Class A common stock. This grant was made to entice the employee to join the company, in compliance with Nasdaq Listing Rule 5635(c)(4).

The stock option’s exercise price corresponds to the closing price of the Company’s Class A shares on the grant date and has a total term of ten years. The vesting schedule stipulates that 25% of the shares will vest on the one-year anniversary of the vesting commencement date, with the remaining shares vesting monthly over the subsequent 36 months, contingent upon the employee's continued service at Contineum.

Contineum Therapeutics is advancing a pipeline of unique oral small molecule therapies aimed at addressing significant unmet medical needs in the NI&I space. Among its clinical candidates, PIPE-791, an LPA1 receptor antagonist, is in development for conditions such as idiopathic pulmonary fibrosis and chronic pain. Meanwhile, PIPE-307, a selective inhibitor of the M1 receptor, is being explored for its potential effectiveness in treating relapsing-remitting multiple sclerosis and major depressive disorder.

For further information, stakeholders can visit the company's website at www.contineum-tx.com or reach out to Steve Kunszabo, Senior Director of Investor Relations & Corporate Communications, for inquiries.

Contineum Therapeutics, Inc. (NASDAQ: CTNM) recently announced an inducement grant under Nasdaq Listing Rule 5635(c)(4), awarding a non-qualified stock option to a new non-executive employee. This strategic move highlights the company’s strong focus on talent acquisition, essential for its growth trajectory in the clinical-stage biopharmaceutical sector, particularly in neuroscience, inflammation, and immunology.

The inducement grant, which entails a stock option to purchase 23,000 shares at the closing price on January 26, 2026, serves as both a recruitment tool and a means to align employee interests with shareholder value. With a four-year vesting schedule, including a one-year cliff and monthly vesting thereafter, this structure incentivizes long-term commitment from employees while ensuring their contributions are tied to the company's performance.

Given Contineum's focus on developing novel therapies for significant unmet medical needs, such as PIPE-791 for idiopathic pulmonary fibrosis and PIPE-307 for relapsing-remitting multiple sclerosis, the new hire could play a pivotal role in advancing these promising candidates. As these programs progress in clinical trials, positive results could substantially impact the company’s market valuation, especially in a competitive landscape where innovation drives investment.

Investors should closely monitor the progress of Contineum's clinical trials and the overall execution of its strategic initiatives. The inducement grant signifies the potential for unlocking greater shareholder value through successful product development and market launch. An analysis of key financial health indicators and clinical milestones should guide investment decisions, as positive news could serve as a catalyst for stock price appreciation. Moreover, in an environment increasingly focused on biotechnology innovation, maintaining a diversified portfolio that includes players like Contineum could yield potential rewards as the market evolves.